Redstone

Redstone is a Berlin-based venture capital firm founded in 2014, with additional offices in Zurich and Helsinki. It specializes in early-stage European companies across various sectors, including health, industrial, and fintech. Redstone has developed a unique VC-as-a-Service model that bridges the gap between industry leaders and ambitious entrepreneurs, facilitating access to corporate capital, expertise, and networks. The firm combines investment services with tailored intelligence, helping its partners make informed strategic decisions and stay abreast of emerging digital trends. With a team of experienced entrepreneurs and investors deeply embedded in the European technology ecosystem, Redstone aims to identify and support promising ventures that align with its investment strategies. The firm emphasizes fast and transparent communication, fostering trust with both startups and investors.

Stefano Gurciullo

Partner

Lars Häerle

COO, Partner

Oskari Lehtonen Ph.D

Partner, Nordics

Past deals in Zurich

Westhive AG

Series A in 2022
Westhive provides superior flexible workspace solutions. Westhive has been conceived to be more than just a coworking space. The aim was to create an innovation ecosystem for startups, corporations and freelancers in which they can share their thougths, collaborate and bring great ideas to life. This is why we paid great attention the setup of the space. The dedicated work areas allow for concentrated focus, whereas our lounges and our restaurant – The Westhive Kitchen – are perfect for informal exchange with fellow coworkers and creative breaks with food and drinks alike. The perfect balance of work and play. Westhive has been created as a space that we as founders would love to work in as well. Which we will.

Pregnolia

Series A in 2020
Pregnolia AG is a Swiss company specializing in the development of diagnostic devices aimed at predicting the risk of premature birth during pregnancy consultations. Founded in 2015 and based in Zurich, the company has created a medical probe that measures the stiffness of the uterine cervix, which is a critical factor in assessing cervical status and mitigating the risk of premature delivery. This technology enables gynecologists to make informed decisions regarding birth management, ultimately improving neonatal health outcomes. Pregnolia's mission is to ensure that every woman can experience a healthy and informed pregnancy, as they work towards completing clinical trials and navigating regulatory processes to bring their product to market. The company focuses on addressing both health and economic challenges associated with preterm birth, aiming to enhance the care provided by doctors and midwives globally.